GlassScriptPhysician profile
Judy Lane
NPI 1407819584
$343,543.43
in general payments reported to CMS, 2019-2025
65 companies · $710 in 2025
The $710 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $52K · 2021: $91K · 2022: $67K · 2023: $22K · 2024: $6,603 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $6,764 · Honoraria: $1,700 · Travel and Lodging: $99.47 · Education: $24.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,825.00 |
| Food and Beverage | $6,764.38 |
| Honoraria | $1,700.00 |
| Travel and Lodging | $99.47 |
| Education | $24.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $93,594.80 | 2019-2024 | Emgality, Kisunla, Reyvow |
| Amgen INC. | $62,307.44 | 2019-2023 | Aimovig, Otezla |
| Biohaven Pharmaceuticals, INC. | $44,256.15 | 2020-2021 | |
| Abbvie INC. | $35,371.74 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27,277.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $24,997.41 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Lundbeck LLC | $23,398.49 | 2020-2025 | Vyepti, Rexulti |
| Allergan, INC. | $11,163.23 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $5,846.22 | 2022 | |
| Upsher-Smith Laboratories LLC | $2,801.18 | 2020-2023 | |
| Currax Pharmaceuticals LLC | $2,296.79 | 2020-2023 | Onzetra Xsail |
| Bausch Health US, LLC | $1,479.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $921.36 | 2019-2023 | |
| Biogen, INC. | $889.51 | 2019-2023 | Vumerity, Tysabri |
| Pfizer INC. | $673.49 | 2023-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judy Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.